چكيده به لاتين
Recent advances in drug delivery systems have positioned them as innovative therapeutic methods, capturing the interest of numerous researchers. There is a concerted effort to replace conventional therapeutic approaches with these systems for specific diseases that often present challenging treatment options. Erlotinib, an anticancer agent, is utilized in the treatment of various types of cancer, including lung cancer, which ranks among the leading causes of cancer-related deaths worldwide. Due to its very low water solubility, erlotinib presents challenges for gastrointestinal absorption. To address this issue, drug delivery systems are employed to enhance absorption. In this study, porous polylactic acid (PLA) microspheres were selected as the drug carrier due to the biodegradability and biocompatibility of PLA. Additionally, magnetite nanoparticles were incorporated to facilitate targeted drug delivery. To evaluate the proposed method, a specific amount of erlotinib was loaded onto the prepared substrate and quantified using UV-Vis spectroscopy. The drug release rate from the final structure was investigated in different pH buffers (7.4 and 5.4) over various time points (1, 2, 3, 4, 6, 8, 24, 48, 72, 96, 144, and 192 hours). The encapsulation efficiency of the drug was found to be 98.5%, with a drug loading percentage of 69.4%. Drug release at pH 7.4 was observed to be 26.11% within the first 24 hours, increasing to 48.53% after 144 hours. In contrast, at pH 5.4, the release was 45.32% in the first 24 hours and reached 73.1% after 144 hours.
